Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Life Sciences	$2.32 +0.4%	$1.54	$1.03 ▼ $2.57	$464.78M	1.22	1.61 million shs	1.80 million shs
DSGN Design Therapeutics	$4.01 +0.3%	$3.70	$2.60 ▼ $7.77	$227.64M	1.77	185,125 shs	62,267 shs
ORIC ORIC Pharmaceuticals	$7.97 +33.5%	$5.35	$3.90 ▼ $14.67	$566.57M	1.37	723,412 shs	14.45 million shs
RLYB Rallybio	$0.32 -5.3%	$0.35	$0.22 ▼ $1.73	$13.28M	-1.28	111,997 shs	239,709 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Life Sciences	+0.43%	+14.85%	+64.54%	+34.88%	+42.33%
DSGN Design Therapeutics	+0.25%	+3.62%	-8.66%	-17.49%	+4.16%
ORIC ORIC Pharmaceuticals	+33.50%	+33.95%	+40.81%	-0.75%	-5.68%
RLYB Rallybio	-5.34%	-3.33%	+4.90%	-55.84%	-78.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI Atai Life Sciences	2.4324 of 5 stars	3.7	1.0	0.0	2.7	2.5	0.6
DSGN Design Therapeutics	0.4201 of 5 stars	1.0	0.0	0.0	2.2	2.5	0.6
ORIC ORIC Pharmaceuticals	3.7042 of 5 stars	3.5	0.0	4.3	3.0	1.7	0.6
RLYB Rallybio	2.8165 of 5 stars	3.0	4.0	0.0	2.7	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI Atai Life Sciences	3.33	Buy	$8.67	273.56% Upside
DSGN Design Therapeutics	2.00	Hold	$4.00	-0.25% Downside
ORIC ORIC Pharmaceuticals	3.00	Buy	$19.17	140.49% Upside
RLYB Rallybio	2.00	Hold	$10.00	3,034.80% Upside

Current Analyst Ratings Breakdown

Latest RLYB, ATAI, DSGN, and ORIC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	ORIC ORIC Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
5/20/2025	ATAI Atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
5/20/2025	ATAI Atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/13/2025	ATAI Atai Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/6/2025	ORIC ORIC Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $12.00
5/6/2025	ORIC ORIC Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/5/2025	ORIC ORIC Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $21.00
4/15/2025	RLYB Rallybio	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/13/2025	RLYB Rallybio	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/9/2025	RLYB Rallybio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
4/8/2025	RLYB Rallybio	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI Atai Life Sciences	$1.86M	249.48	N/A	N/A	$1.47 per share	1.58
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$4.96 per share	N/A
ORIC ORIC Pharmaceuticals	N/A	N/A	N/A	N/A	$3.42 per share	N/A
RLYB Rallybio	$848K	15.65	N/A	N/A	$2.81 per share	0.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI Atai Life Sciences	-$40.22M	-$0.91	N/A	N/A	N/A	N/A	-65.75%	-52.71%	8/12/2025 (Estimated)
DSGN Design Therapeutics	-$66.86M	-$0.99	N/A	N/A	N/A	N/A	-18.01%	-17.38%	8/4/2025 (Estimated)
ORIC ORIC Pharmaceuticals	-$100.70M	-$1.87	N/A	N/A	N/A	N/A	-44.54%	-40.72%	8/11/2025 (Estimated)
RLYB Rallybio	-$74.56M	-$1.09	N/A	N/A	N/A	N/A	-77.39%	-69.33%	8/14/2025 (Estimated)

Latest RLYB, ATAI, DSGN, and ORIC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ATAI Atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million
5/14/2025	Q1 2025	DSGN Design Therapeutics	-$0.28	-$0.31	-$0.03	-$0.31	N/A	N/A
5/8/2025	Q1 2025	RLYB Rallybio	-$0.21	-$0.21	N/A	-$0.21	N/A	$0.21 million
5/5/2025	Q1 2025	ORIC ORIC Pharmaceuticals	-$0.51	-$0.42	+$0.09	-$0.42	N/A	N/A
3/17/2025	Q4 2024	ATAI Atai Life Sciences	-$0.14	-$0.24	-$0.10	-$0.24	$0.30 million	($0.01) million
3/13/2025	Q4 2024	RLYB Rallybio	-$0.27	-$0.25	+$0.02	-$0.25	$0.15 million	$0.04 million
3/10/2025	Q4 2024	DSGN Design Therapeutics	-$0.28	-$0.24	+$0.04	-$0.24	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI Atai Life Sciences	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
ORIC ORIC Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RLYB Rallybio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI Atai Life Sciences	0.14	5.81	5.81
DSGN Design Therapeutics	N/A	34.61	34.61
ORIC ORIC Pharmaceuticals	N/A	10.56	13.15
RLYB Rallybio	N/A	9.55	9.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI Atai Life Sciences	28.41%
DSGN Design Therapeutics	56.64%
ORIC ORIC Pharmaceuticals	95.05%
RLYB Rallybio	90.34%

Insider Ownership

Company	Insider Ownership
ATAI Atai Life Sciences	31.20%
DSGN Design Therapeutics	31.20%
ORIC ORIC Pharmaceuticals	6.82%
RLYB Rallybio	8.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI Atai Life Sciences	80	200.34 million	115.45 million	Optionable
DSGN Design Therapeutics	40	56.77 million	38.96 million	Optionable
ORIC ORIC Pharmaceuticals	80	71.09 million	67.09 million	Optionable
RLYB Rallybio	40	41.61 million	38.42 million	Not Optionable

RLYB, ATAI, DSGN, and ORIC Headlines

Recent News About These Companies

Rallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlook

May 24, 2025 | investing.com

Rallybio shareholders elect directors, ratify auditor

May 18, 2025 | uk.investing.com

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 9, 2025 | finance.yahoo.com

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

April 29, 2025 | finance.yahoo.com

Jones Trading Downgrades Rallybio (RLYB)

April 15, 2025 | msn.com

Rallybio downgraded to Hold from Buy at JonesResearch

April 14, 2025 | markets.businessinsider.com

Rallybio downgraded to In Line from Outperform at Evercore ISI

April 12, 2025 | markets.businessinsider.com

Rallybio (RLYB) was downgraded to a Hold Rating at H.C. Wainwright

April 10, 2025 | markets.businessinsider.com

Rallybio Stock Short Interest Report | NASDAQ:RLYB | Benzinga

April 9, 2025 | benzinga.com

Rallybio discontinues RLYB212 program

April 9, 2025 | markets.businessinsider.com

Rallybio sinks as it drops RLYB212 for prevention of FNAIT

April 9, 2025 | thepharmaletter.com

HC Wainwright & Co. Downgrades Rallybio (RLYB)

April 9, 2025 | msn.com

RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks

April 9, 2025 | zacks.com

Citizens JMP downgrades Rallybio on RLYB212 discontinuation

April 9, 2025 | markets.businessinsider.com

JMP Securities downgrades Rallybio (RLYB) to a Hold

April 9, 2025 | theglobeandmail.com

Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints

April 8, 2025 | benzinga.com

Rallybio Discontinues Development of Treatment for Prevention of Rare Immune Disorder

April 8, 2025 | marketwatch.com

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

April 8, 2025 | finance.yahoo.com

Rallybio reports Q4 EPS (25c), consensus (30c)

March 13, 2025 | markets.businessinsider.com

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

March 13, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLYB, ATAI, DSGN, and ORIC Company Descriptions

Atai Life Sciences NASDAQ:ATAI

$2.32 +0.01 (+0.43%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$2.31 -0.01 (-0.43%)

As of 05/29/2025 07:59 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Design Therapeutics NASDAQ:DSGN

$4.01 +0.01 (+0.25%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$4.01 +0.00 (+0.12%)

As of 05/29/2025 04:02 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

ORIC Pharmaceuticals NASDAQ:ORIC

$7.97 +2.00 (+33.50%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$7.98 +0.01 (+0.13%)

As of 05/29/2025 07:59 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Rallybio NASDAQ:RLYB

$0.32 -0.02 (-5.34%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$0.32 0.00 (-0.63%)

As of 05/29/2025 06:19 PM Eastern

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time